Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
112M
-
Number of holders
-
404
-
Total 13F shares, excl. options
-
82M
-
Shares change
-
+379K
-
Total reported value, excl. options
-
$3.3B
-
Value change
-
-$89.7M
-
Put/Call ratio
-
0.66
-
Number of buys
-
206
-
Number of sells
-
-210
-
Price
-
$40.24
Significant Holders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) as of Q4 2024
543 filings reported holding VKTX - Viking Therapeutics, Inc. - COMMON STOCK as of Q4 2024.
Viking Therapeutics, Inc. - COMMON STOCK (VKTX) has 404 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 82M shares
of 112M outstanding shares and own 72.99% of the company stock.
Largest 10 shareholders include FMR LLC (16.7M shares), VANGUARD GROUP INC (10.2M shares), BlackRock, Inc. (5.87M shares), STATE STREET CORP (4.93M shares), MORGAN STANLEY (2.59M shares), JPMORGAN CHASE & CO (2.16M shares), GEODE CAPITAL MANAGEMENT, LLC (1.88M shares), CITADEL ADVISORS LLC (1.49M shares), BRAIDWELL LP (1.48M shares), and AMERIPRISE FINANCIAL INC (1.48M shares).
This table shows the top 404 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.